ArticleJournal of experimental & clinical cancer research : CR2023

GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.

Xiayun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.